Jump to Header Jump to Main Content Jump to Footer

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Interstitial Pulmonary Fibrosis

Huawei Dong


A Study On:

  • Lung - Pulmonary

Status:

  • Open

Eligibility

Idiopathic Pulmonary Fibrosis
40 Years and older (Adult, Older Adult)

Interested in joining this trial?

Official Title

A randomized, double-blind, placebo-controlled, study to investigate the safety, pharmacokinetics, and pharmacodynamics of CSL312 in subjects with idiopathic pulmonary fibrosis

Details

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).


Eligibility

You can join if...

Inclusion Criteria:

  1. Male or female patients ≥ 40 years of age
  2. Documented diagnosis of IPF

Exclusion Criteria:

  1. History of clinically significant cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina during the 6 months before screening
  2. Sinoatrial or atrioventricular block, uncontrolled hypertension
  3. Active bleeding or current clinically significant coagulopathy

Get in touch with our study team